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Summary
Chromosome rearrangements associated with neo-
plasms provide a rich resource for definition of the path-
ways of tumorigenesis. The power of comparative ge-
nome hybridization (CGH) to identify novel genes
depends on the existence of suitable markers, which are
lacking throughout most of the genome. We now report
a general approach that translates CGHdata into higher-
resolution genomic-clone data that are then used to de-
fine the genes located in aneuploid regions. We used
CGH to study 33 thyroid-tumor DNAs and two tumor-
cell-line DNAs. The results revealed amplifications of
chromosome band 2p21, with less-intense amplification
on 2p13, 19q13.1, and 1p36 and with least-intense am-
plification on 1p34, 1q42, 5q31, 5q33-34, 9q32-34, and
14q32. To define the 2p21 region amplified, a dense
array of 373 FISH-mapped chromosome 2 bacterial ar-
tificial chromosomes (BACs) was constructed, and 87 of
these were hybridized to a tumor-cell line. Four BACs
carried genomic DNA that was amplified in these cells.
The maximum amplified region was narrowed to 3–6
Mb by multicolor FISH with the flanking BACs, and
the minimum amplicon size was defined by a contig of
420 kb. Sequence analysis of the amplified BAC 1D9
revealed a fragment of the gene, encoding protein kinase
C epsilon (PKCe), that was then shown to be amplified
and rearranged in tumor cells. In summary, CGH com-
bined with a dense mapped resource of BACs and large-
scale sequencing has led directly to the definition of
PKCe as a previously unmapped candidate gene involved
in thyroid tumorigenesis.
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Introduction
The association of specific chromosome abnormalities
with particular types of human cancer has been estab-
lished by investigators during the past decade (Mitelman
1994; Kallioniemi 1997). Such abnormalities can be
characterized as changes in gene copy number that are
due to either amplifications or deletion, such as those
encoding oncogenes or tumor-suppressor genes, respec-
tively (Gordon et al. 1994), or as translocations and
other rearrangements, long known to be an important
feature of certain hematologic malignancies (Brodeur et
al. 1984; Bishop 1987; Slamon et al. 1989; Oliner et al.
1992).
Thyroid neoplasms represent an attractive model for
the study of the molecular genetics of tumorigenesis,
since they constitute a broad spectrum of phenotypes,
ranging from benign follicular adenomas to the uni-
formly fatal anaplastic thyroid carcinomas. Current
genetic studies indicate that the development and pro-
gression of thyroid tumors is signaled by phenotype-
specific mutations of genes involved in growth control
(Fagin et al. 1994).
Approximately 10% of the population develops pal-
pable thyroid nodules during their lifetime. More than
12,000 new cases of thyroid cancer develop each year
in the United States, for which scant information on
cytogenetic abnormalities is available. Although, during
the past few years, significant progress has been made
in the identification of somatic-gene defects associated
with various human thyroid-tumor phenotypes (Fagin
et al. 1993), the diagnostic tools available to distinguish
benign from malignant neoplasms are not reliable, re-
sulting in a large number of unnecessary surgeries. Point
mutations of ras oncogenes are believed to be important
initiating events in thyroid-tumor formation (Lemoine
et al. 1989; Namba et al. 1990; Suarez et al. 1990), and
mutational activation of ras has been shown to promote
genomic instability and gene amplification (Finney and
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Bishop 1993; Denko et al. 1994). However, screening
studies for potentially amplified regions in thyroid tu-
mors have relied on candidate-gene markers and have
been mostly unrewarding (Namba et al. 1990).
CGH is a recently described molecular-cytogenetic
technology that globally assays for chromosomal gains
and losses in solid tumors when chromosome prepara-
tions are not feasible (Kallioniemi et al. 1992, 1994b).
Application of CGH to DNAs extracted from tumor
specimens has revealed a number of chromosomal ab-
errations and imbalances that were undetected by tra-
ditional cytogenetic analysis. These findingswarrantmo-
lecular-genetic studies aimed at isolation of the perturbed
genes (Houldsworth and Chaganti 1994; Kallioniemi et
al. 1994a; Ried et al. 1995, 1996; Voorter et al. 1995;
Schrock et al. 1996). CGH has been used also to identify
tumor-specific genetic markers and to evaluate the role
of known genes in tumor diagnosis, prognosis, and pro-
gression (Forus et al. 1995; Visakorpi et al. 1995; Boer-
man et al. 1996; Ghazvini et al. 1996; Koivisto et al.
1997). In order to define candidate genes or regions in-
volved in the chromosomal imbalance, FISH analyses
have been performed on tumor samples (Tanner et al.
1994, 1996; Jossart et al. 1995, 1996; Taniwaki et al.
1995). However, despite the power of CGH for whole-
genome analyses, no previously unmapped novel tumor
gene has been identified by this approach. This limited
ability to rapidly translate the global CGH approach
into the identification of candidate genes has been ham-
pered both by the low resolution of regional assignment
of amplification and by the lack of large arrays of stable
genomic clones located in the unbalanced regions.
To remedy this, we report an approach to tumor-gene
discovery, after CGH, that combines the construction
and application of a chromosome 2 high-density re-
source of mapped bacterial artificial chromosomes
(BACs) (Chen et al. 1996) and large-scale sequencing,
to investigate amplified sequences. By this approach,
PKCe (the gene for protein kinase C epsilon) has been
identified as a candidate for thyroid tumorigenesis (J. A.
Knauf, R. Elisei, D. Mochly-Rosen, T. Liron, X.-N.
Chen, J. R. Korenberg, and J. A. Fagin, unpublished
data).
Material and Methods
Cell- and Tissue-Sample Collection
Human thyroid tumors were collected at the time of
surgery and immediately were frozen in liquid nitrogen.
Whenever possible, samples were taken from both the
tumor and the normal tissue from the same individual.
Histopathologic diagnosis was confirmed independently
by at least two pathologists. Tissues used for the current
study are listed in the Appendix. Samples for DNA ex-
traction were taken from within the tumor nodules, at
sites distant from the margins of the lesion. Represen-
tative sections were examined to ensure that the samples
did not include normal thyroid or non-neoplastic tissue.
Papillary carcinomas contain a variable admixture of
stromal cells, but usually x70% were tumor cells. The
human thyroid carcinoma cell lines ARO and WRO
were originally obtained from G. Juilliard (UCLA) and
were propagated in RPMI-1640 medium containing
10% FCS, glutamine (286 mg/liter), and Fungi-Bact (Ir-
vine Scientific, CA), as described by Zeki et al. (1994).
DNA Extraction and Southern Blot Analysis
DNA from snap-frozen thyroid tissue was prepared
by use of the guanadinium-CsCl procedure (Davis et al.
1986). Southern blot analyses were performed as de-
scribed elsewhere (Southern 1975). In brief, 10 mg of
EcoRI-digested DNA was electrophoresed on a 0.9%
agarose gel and were transferred to a nylon membrane.
Membranes were hybridized with the indicated [32P] ran-
dom-primed probe, as described by the manufacturer
(Strategene). After being washed at high stringency, blots
were exposed to XAR-5 or Kodak BMR-1 films (East-
man Kodak).
CGH to Determine Chromosomal Regions Potentially
Amplified in the Tumor
The CGH procedure was modified from that of Kal-
lioniemi et al. (1992). To increase the resolution of CGH
and to facilitate the subsequent assignment of mapped
BACs to putatively amplified regions, the present study
replaced the standard DAPI counterstain with a higher-
resolution reverse-banding technique (Korenberg and
Chen 1995). A total of 33 tumors and two cell lines
were analyzed by CGH (see the Appendix). For each,
the hybridization signal from the tumor or cell-lineDNA
was compared with germ-line DNA from either normal
thyroid tissue or peripheral blood of the corresponding
individual. When matched samples were not available,
sex-matched control DNAs were used. To evaluate for
abnormal ratios due to target structure or probe com-
position, control experiments were performed first, with
normal genomic DNAs used as the competing probes.
DNA labeling, hybridization, and detection were per-
formed as described by Kallioniemi et al. (1992).
High-Resolution Banding and Image Acquisition for
CGH
High-resolution chromosome identification was
achieved by staining of slides, at room temperature, with
chromomycin A3 (0.3 mg/ml in 1/2xMcILavane’s buffer
pH 9.0) for 15min, followed by stainingwith distamycin
A (0.1 mg/ml in 1/2 McILavane’s buffer, pH 9.0) for 1
min, a modified reverse-banding technique described
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Table 1
Aneuploid Regions in Thyroid-Tumor and Cell-Line DNAs
ANEUPLOID
REGION
NO. OF CASES
POSITIVE
DNA
(%)
Follicular
Adenoma
( )n  10
Follicular
Carcinoma
Papillary
Carcinoma
( )n  16
Anaplastic Tumor
Total
( )n  32
Tissue
( )n  4
Cell Line
( )n  1
Tissue
( )n  1
Cell Line
( )n  1
Amplified ( ):green/red 1 1.5
1p34 2 2 ) 4 ) ) 9 28
1p36 3 2 ) 5 ) ) 10 31
1q42 3 2 ) 4 ) ) 9 28
2p21 4 ) 1 4 ) ) 9 28
2p13 1 ) 1 3 ) ) 5 16
5q31 2 ) ) 3 ) ) 5 16
5q33)34 1 ) ) 4 ) ) 5 16
9q32)34 3 ) ) 4 ) ) 7 22
14q32 3 ) ) 5 ) ) 8 25
16q22)24 1 ) ) 4 ) ) 5 16
19q13.1 5 ) ) 8 ) ) 13 41
Deleted ( ):green/red ! .5
16q12)13 5 ) ) 3 ) ) 8 25
elsewhere (Korenberg and Chen 1995). Three-color im-
ages including the CGH ratio were captured by a Pho-
tometrics cooled charge-coupled device (CCD) camera
(CH250) and Oncor Imaging analysis system equipped
with a Zeiss 135 Axiovert fluorescencemicroscope.First,
the images of reversed-banded chromosomes were ac-
quired by means of Zeiss filter set 5 (exciter 400–440
nm). To do this, the counterstain was used at low con-
centration for a short time, so that the banding faded
rapidly after image capture by the CCD camera. The
hybridization signals then were captured independently
by means of a triple-bandpass filter (P/N 61002; Chroma
Technology), with no interference from the banding sig-
nal. A second banding image, of lower resolution, was
then collected by means of a long exposure through the
same triple-bandpass filter and was used to register the
high-resolution–banding image with the CGH images.
The three images were then independently recalled and
were evaluated both for the existence of amplification
(comparison of tumor DNA with germ-line DNA) and
for its precise location on the banded chromosomes. To
assure proper registration (X-and-Y–shift pixel number),
the second image, representing both the banding and
FITC signals simultaneously, was acquired, with longer
exposure times, by means of the second dichroic filter
(497 nm; exciter filter FITC-HQ) that also was used to
acquire the final CGH signals. This second image pro-
cedure effectively quenches the chromomycin banding
signals (data not shown) and prevents the chromomycin
emission from interfering with the subsequent acquisi-
tion of the CGH-signal ratios. The FITC and rhodamine
images were then taken for CGH-signal ratios calcula-
tion by means of the same dichroic/emitter set but with
a different excitation filter (P/N 81P490 for FITC-SB and
P/N 81P570 for Texas Red-SB), to obviate the effects of
movement of the dichroic filter. To define the pixel shift
between dichroic sets and to generate accurate band as-
signments, the FITC/chromomycin signal was superim-
posed on the chromomycin signal, and this position used
to superimpose the CGH images on the banding pat-
terns. Finally, for illustration, the banding image was
shifted to show the amplified or deleted regions clearly.
CGH-Signal Ratio Analysis
The Oncor Imaging system (version 1.6) was used for
CGH-signal ratio analysis. Images were acquired and
superimposed for the tumor and control DNA hybrid-
izations on a total of 10-20 cells for each tumor DNA
and cell-line DNA and were evaluated for technical ad-
equacy (i.e., strength and smoothness of hybridization
signals from both the tumor and control DNAs—as well
as quality of the chromosomal spread, including very
well-spread chromosomes at the 500-band stage). The
images of four representative cells of each tested DNA
were then selected and saved for detailed visual analyses
and for digitized CGH-signal ratio determination, re-
sulting in a total of 140 cells included in the analyses
(table 1). The analysis of CGH-signal ratio and color
was done by an investigator who was blind to the tumor
types and to the previously amplified or deleted regions.
Regions were visually considered as candidates for am-
plification or deletion by virtue of their intensity of signal
and yellow color on the registered images of tumor DNA
versus normal control DNA. For each saved cell, the
putatively aneuploid chromosome bands were then con-
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firmed by digitized CGH images as amplified or deleted
and were then recorded for each cell. This was done in
part to accommodate the inability of the availableOncor
Imaging system CGH software to average signals across
multiple cells. Ratios 11.5 were considered as indicative
of amplification whereas those !0.5 were considered as
indicative of deletion, when the observed ratio was ∼1.0
for the remainder of the chromosome. However, signif-
icant ratios acquired from the telomere and centromere
regions were not considered positive, in view of the ex-
istence of artificial ratios in these regions, although this
may result in missing some rearrangements. Further-
more, because regions initially were selected visually,
some more-subtle changes in copy number may have
gone undetected.
Chromosome 2 BAC-Library Construction
Further analysis was focused on the highly amplified
region of chromosome band 2p21. To assist in the map-
ping and defining of genomic clones for the regions, a
chromosome 2 BAC map was constructed as described
elsewhere (Wang et al. 1994). This collection was en-
larged to 373 by the addition of 32 members. Each BAC
was mapped, by FISH, to a 2–6-Mb region of chro-
mosome 2.
Size Estimation of Amplified Region, by Dual-Color
FISH
The cohybridization of the closest flanking BAC
clones that were not amplified was performed according
to procedures described elsewhere (Korenberg and Chen
1995). BAC 1D9 was biotin labeled, and BACs 401E9
or 2B5 were digoxigenin labeled. The probe combina-
tion of 1D9 with either 401E9 or 2B5 was hybridized
simultaneously to chromosome slides made with a sam-
ple from a normal male, and images were collected as
described above. In addition, we have searched the
Whitehead sequence-tagged-site (STS)–map database
(Whitehead Institute for Biomedical Research/MIT Cen-
ter for Genome Research) to which our BAC resource
was linked. The distance between two flanking STSs in
the region was defined on a radiation-hybrid (RH) map
and the genetic maps (Whitehead Institute for Biomed-
ical Research/MIT Center for Genome Research).
BAC Characterization
Two BAC libraries (Shizuya et al. 1992; Wang et al.
1994) and a single P1-derived artificial chromosome
(PAC) library were used (Research Genetics [Ioannou et
al. 1994]). The BAC library was arrayed at a high density
of 8#12-cm nylon-membrane filters. The majority of
the BAC and PAC clones in the region were identified,
by means of a single-copy fragment derived from PKCe
cDNA, as hybridization probes (J. A. Knauf, R. Elisei,
D. Mochly-Rosen, T. Liron, X.-N. Chen, J. R. Koren-
berg, and J. A. Fagin, unpublished data). BACs and PACs
were prepared from NotI/EcoRI digests, and BAC-to-
BAC or BAC-to-PAC Southern blotting was performed
as described above. A total of 18 positive clones were
analyzed by FISH, and only those both mapping to 2p21
and amplified on double minute chromosomes (DMs)
were characterized further.
BAC Sequencing and Gene Identification
BAC 1D9 was sequenced by means of a modified shot-
gun sequencing strategy, as described elsewhere (Chissoe
et al. 1997; Wilson and Mardis 1997). This entailed
initial sequencing of random plasmid or M13 subclones.
BAC DNA was sonicated, and the resulting end-repaired
fragments were ligated to eitherM13 or plasmid vectors.
M13 DNA was prepared by the ThermoMAX method,
which involved nonionic detergent denaturation of poly-
ethylene glycol–precipitated phage particles (Mardis
1994). Plasmid DNA was prepared by the AGCT 96-
well boiling Miniprep method (Advanced Genetic Tech-
nologies). Sequitherm-catalyzed (Epicenter Technolo-
gies) fluorescent-dye–primer cycle-sequencing reactions
(Fulton and Wilson 1994) using plasmid or M13 tem-
plate DNA were electrophoresed by ABI 373A Sequenc-
ers (Perkin-Elmer, Applied Biosystems), with which the
data automatically were collected and analyzed. Data
processing was performed by OTTO script (L. Hillier,
personal communication), which assessed trace quality,
performed vector clipping, and assembled sequence data
by XBAP (Dear and Staden 1991). Gaps were closed by
directed dye-primer or dye-terminator sequencing re-
actions, by means of mapped subclone DNA or DNA
fragments generated either by PCR amplification of BAC
DNA or by mapped subclone DNA. The sequence was
edited within the XBAP-database interface. All regions
of the finished sequence were covered by more than one
subclone, either sequenced in opposite orientations or
by means of alternative chemistries. Restriction-frag-
ment–digestion analysis was used to verify final sequence
assembly. The sequence was then screened against
GenBank 2 EMBL (BLAST X1.47mp). The known can-
didate genes lying within 2p21 and 2p13 also were ex-
amined for amplification in WRO cells, by Southern
blotting.
Results
DNA-Copy-Number Changes Detected by CGH
The DNAs isolated from a total of 33 tumors and
from two cell lines were analyzed by CGH (see the Ap-
pendix). To minimize false-positive results, the list in-
cludes only regions that were found to be aneuploid in
two or more tumor DNAs and in two or more cells for
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Figure 1 Mapping of amplifications on chromosome 2 in the
thyroid follicular-carcinoma cell line, WRO, by CGH. Illustrated is a
reverse-banded chromosome image side-by-side with the correspond-
ing tumor-DNA hybridization image obtained with WRO DNA. The
amplified region is indicated by arrows aligned with chromosome
bands 2p21 and 2p13.
each given DNA. The ratios from the control experi-
ments showed no changes 11.2, for any chromosomal
region. All test DNAs were used in at least two inde-
pendent experiments—with the exception of two follic-
ular carcinomas (J3 and J4), which, because of limited
DNA amounts, allowed only a single experiment. Be-
cause additional experiments might have confirmed the
regions putatively amplified but observed only in single
cells, these regions are listed here: band 2p25, in single
cells of two of four DNAs; and bands 2p23, 2q35, 3q21-
23, 7q11-21, 8q12-21, and 14q11.2-21, each in only
one of four DNAs.
For 26 tumor DNAs and one cell-line DNA, the visual
inspection suggested a number of possible amplifications
or deletions, each of which then was confirmed by the
digitized CGH ratios, on the basis of the criteria de-
scribed in the Material and Methods section (numerical
data are not shown). These chromosomal regions are
summarized, by chromosome band, in table 1. The total
frequency of amplification for a given region is defined
as the ratio of the number of test DNAs showing this
region to be amplified, versus the total number of tumor
or cell-line DNAs tested. For five of the tumors (one
anaplastic tumor, one follicular carcinoma, two papillary
carcinomas, and one follicular adenoma), no regions
suggesting an amplification were detected either by the
visual inspection of the initial 10–20 cells or on the four
saved images. Three additional tumors showed poor hy-
bridization and, because of the limited amount of tumor
DNA, were not retested.
Eleven regions revealed putative amplifications in
16%–41% of the tumor and cell-line DNAs, and one
revealed a deletion in 25% of DNAs (table 1). The small
number of tumors in each class limited the extent to
which phenotype-specific differences in amplification
patterns could be detected. All tumor types revealed a
similar pattern of regions amplified—with the exception
of the follicular carcinomas, for which the small amounts
of DNA limited the data that could be collected. Chro-
mosome band 19q13.1 revealed the highest incidence of
putative amplification (41%), followed by bands 1p36
(32%), 1p34, 1q42, 2p21 (all seen in 28% of DNAs),
and 14q32 (25%). Chromosome band 16q12-13 ap-
peared consistently decreased in signal (25%).
The amplification of 2p21 and 2p13 seen in the WRO
cell line also was observed in a significant proportion of
thyroid tumors, providing the opportunity to further
narrow the region containing a putative gene involved
in thyroid tumorigenesis. However, further definition of
putatively amplified regions was quite limited in those
tumors that were unaccompanied by archival sections
or cell lines. The 2p21 region was therefore analyzed
more extensively in WRO cells.
The WRO cell line originated from a follicular car-
cinoma and, by standard cytogenetic analyses, was
shown to harbor DMs. Two of the 32 tumors, as well
as the WRO cell line, revealed amplification of band
2p13. Figure 1 illustrates a reverse-banded chromosome
image side-by-side with the corresponding tumor-DNA
hybridization image obtained by use of WRO DNA.
Molecular Definition of the Amplified Region on
Chromosome Band 2p21
In order to define more precisely the regions amplified
on chromosome bands 2p21 and 2p13, as well as their
relationship to the DMs, the regions were further ana-
lyzed, by FISH of BACs. To test for the presence of
sequences throughout chromosome 2, a series of BACs
were mapped, at random, from a chromosome 2–specific
BAC library by FISH (Wang et al. 1994) and were com-
bined with chromosome 2 BACs derived from a whole-
genome, randomly mapped BAC resource (Chen et al.
1996). The distribution of chromosome 2 BACs is il-
lustrated in figure 2. A total of 87 chromosome
band–specific BAC DNAs from this BAC resource then
were tested independently; their locations are shown in
figure 3; of these, 17 were located at regular intervals
spanning the chromosome, 38 mapped to chromosome
band 2p21, 3 to the border of 2p22-21, 2 on the border
of 2p21-p16, and 27 to chromosome band 2p13. The
results indicated that, of the 21 BACs that had been
mapped to 2p21 at random, BAC 1D9 and three ad-
ditional BACs generated signals on the normal chro-
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Figure 2 FISH-mapped chromosome 2 BAC resource. The id-
eogram illustrates a total of 373 BACs randomly mapped on chro-
mosome 2, at 650-band resolution, by FISH. Each dot represents a
single BAC. The dots on the left side represent BACs mapping in the
regions of centromere (c) and telomeres (t’).
mosome 2, as well as on the regions amplified on DMs
in the WRO cell line (fig. 4). This yields an initial BAC
density of ∼1/500–1,000 kb, when it is assumed that
2p21 contains 10–20 Mb of DNA. Although chromo-
some preparations from early passages ofWRO revealed
that 30%–40% of cells contained 40–70 hybridization
signals, in later passages this decreased to 15%–20% of
cells containing 12–50 hybridization signals. None of
the 27 BACs mapped at random to band 2p13–
generated signals on the DMs.
Estimation of the Molecular Limits of the Amplified
Region, by Dual-Color FISH and Genomic Map
Distance
To determine the BACs most closely flanking the am-
plified region, nonamplified BACs mapping on band
2p21 were tested in pairwise combinations with the am-
plified BAC 1D9, by multicolor FISH, in metaphase and
interphase. The results, shown in figure 5, revealed
clearly ordered but overlapping signals for the centro-
meric (BAC 401E9) and telomeric (BAC 2B5) borders.
The closeness but clear separation of signals from this
pair of flanking BACs suggested a maximal distance of
3–6 Mb.
The second approach used to determine the maximum
size of the amplified region was to estimate the distance
between STSs linked to nonamplified BACs that flanked
the amplified region. This was done by reference to the
Whitehead STS (Whitehead Institute for Biomedical Re-
search/MIT Center for Genome Research) and RH
maps. Of the 38 BACsmapping on band 2p21 and tested
for amplification, 3 were found to be linked to STSs
incorporated within the Whitehead maps (Whitehead
Institute for Biomedical Research/MIT Center for Ge-
nome Research). These included the amplified BAC,
1001P2, which carries the STSW5623, and two flanking
nonamplified BACs, 388C11 and 401E9, which are
linked to the STSs WI8407 and WI4284, respectively.
The distance between these markers is 1.6–3.2 Mb, as
estimated on the basis of the RH map (3.7 cR/Mb), and
8–10 Mb (1 cm/Mb), as estimated on the basis of the
Genetic Map.
BAC Characterization and Amplicon
In order to provide further markers with which to
confirm the molecular nature of the amplification event
in 2p21, 18 of 38 BACs mapping in 2p21 were obtained
from library screens by means of whole-BAC DNA from
1D9 and 3′ and 5′ PCR-generated fragments of PKCe,
since exon 1 of this gene was the only expressed fragment
found to be present within the amplified BAC 1D9 (see
below). Nine of these BACs were clearly amplified on
the DMs of WRO, for a total of 13 (including the 4 at
random). Preliminary results with these BAC DNAs and
the PKCe cDNA used as probes on BAC Southern blots
revealed a minimal amplified region of 420 kb, estab-
lished on the basis of the size of all nonoverlapping am-
plified BACs.
BAC Sequencing and Gene Identification
As a first approach to determining the candidate genes
whose amplification was involved in thyroid tumorigen-
esis, BAC 1D9 was sequenced (GenBank accession num-
ber U51244) and was found to consist of 67 kb.
BLASTX analysis (Altschul et al. 1990; Chissoe et al.
1997) of the completed sequence revealed database iden-
tity with human (Basta et al. 1992), rat (Ono et al. 1987),
mouse (Schaap et al. 1989), and rabbit (Ohno et al.
1988) PKCe. The amino acid translation of 1D9 nucle-
otides 13230–13577 matched amino acids 1–116 of
each mentioned PKCe entry, with 100% identity. Pre-
sumably, this represents the first exon of the human
PKCe gene. Additional database similarities identified
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Figure 3 BACs amplified in the thyroid follicular-carcinoma cell
line, WRO. The ideogram shows the cytogenetic locations of a total
of 87 chromosome-band–specific BACs tested onWRO. The amplified
BACs are indicated (red).
Figure 4 Hybridization of BAC 1D9 on WRO chromosome
preparations, showing a distinct pattern of amplification. In addition
to the FITC signals (yellow dots) detected on the three copies of chro-
mosomes 2, on band 2p21, clusters of signals were detected both on
DMs and in adjacent interphase nuclei.
were to other members of the protein kinase family from
human, mouse, and Caenorhabditis elegans. The GC
content within a 2-kb region immediately upstream of
the exon was 68.2%, representing a putative CpG is-
land, compared with an overall GC content of 44.5%
for the entire clone. This exon was then mapped back
to 1D9, and its amplification was confirmed by Southern
blot analysis in the WRO cancer-cell line (fig. 6). Further
exploration of both the frequency of PKCe structural
abnormalities in thyroid cancers and its possible func-
tional consequences will be reported in a separate article
(J. A. Knauf, R. Elisei, D. Mochly-Rosen, T. Liron, X.-
N. Chen, J. R. Korenberg, and J. A. Fagin, unpublished
data).
As a second approach to determining the genes in the
amplified regions, Southern blot analyses with probes
for genes known to map to the region of 2p13 (theMAD
oncogene, TGFa, and the RAL avian reticuloendothe-
liosis viral oncogene homologue) and 2p21 (the carba-
moyl phosphate synthetase asparate transcarbamylase
and dihydrocrotase gene [CAD], the ras guanine nucle-
otide-exchange factor, SOS [Son of Sevenless], and the
DNA-repair enzyme hMSH2) indicated that they were
not involved in the amplification event (data not shown).
Although exon 1 on PKCe was found within BAC 1D9,
it was not detected by exon trapping, presumably be-
cause of the lack of splice-donor/-acceptor sites in the 5′
end of the first exon of this gene (J. A. Knauf, R. Elisei,
D. Mochly-Rosen, T. Liron, X.-N. Chen, J. R. Koren-
berg, and J. A. Fagin, unpublished data). Since BAC 1D9
contains 12 kb of the PKCe upstream region, it may also
contain the ends of the amplicon for this amplification
event. To determine this, the two ends of BAC 1D9 were
sequenced and were tested for amplification on Southern
blots of WRO genomic DNA, and both were found to
be amplified.
Identification of a Chimeric PKCe in the WRO Cell
Line
To investigate the possible involvement and/or rear-
rangement of PKCe in the amplification events, a full-
length human PKCe cDNA was hybridized to Southern
blots containing DNAs from the WRO cell line, the an-
aplastic thyroid carcinoma cell line, and normal tissue
(fig. 6). These demonstrated that the PKCe gene had
undergone rearrangement and amplification in theWRO
cells, since there were additional bands found in the
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Figure 5 Dual-color FISH mapping of BACs most closely flanking 1D9 on 2p21. A, BAC 2B5 (pink), mapping distal to but partially
overlapping BAC 1D9 (green). B, BAC 401E9 (green), mapping proximal to but overlapping BAC 1D9 (pink). C, Two flanking BACs (BAC
401E9 [green] and BAC 2B5 [pink]), which map close to one another but are clearly separated.
WRO cell line that were not found in normal tissue (fig.
6). The detailed characterization of this abnormality and
of its phenotypic impact is shown in the work of J. A.
Knauf, R. Elisei, D. Mochly-Rosen, T. Liron, X.-N.
Chen, J. R. Korenberg, and J. A. Fagin, (unpublished
data). These results provided the basis for further in-
vestigation of PKCe as a candidate gene for thyroid
tumorigenesis.
Discussion
There have been major gaps in our understanding of
the biological behavior of thyroid tumors, resulting in
diagnostic inaccuracy and uncertainty as to the best
treatment for the various forms of the disease. There
have been no previous reports of homogeneously stain-
ing regions or DMs representing highly amplified chro-
mosomal regions (Schimke 1988) in any thyroid neo-
plasms, as determined by cytogenetic analysis (Fagin et
al. 1993).
The power of the approach presented in this study is
in the ability to begin with a single tumor-derived cell
line containing amplified regions and a series of tumor
DNAs and to use CGH coupled with a high-density
mapped array of BACs and genomic sequencing to define
both the regions of amplification and the genomic re-
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Figure 6 Confirmation of amplification event on WRO, by
Southern blot hybridization of DNA from normal lymphocytes (N)
and thyroid carcinoma cell lines (ARO and WRO), digested with
HindIII and probed with full-length PKCe cDNA. Note the amplifi-
cation of selected bands and of aberrantly sized restriction fragments,
indicative of a rearrangement. As expected, no amplification is seen
in ARO.
agents with which to identify and test the genes involved
in the pathways of tumor formation. Our approach has
rapidly defined a BAC, 1D9, and has mapped the gene
for PKCe, which subsequently has been shown to have
significant phenotypic effects consistent with a tumor-
promoting action in thyroid cells (J. A. Knauf, R. Elisei,
D. Mochly-Rosen, T. Liron, X.-N. Chen, J. R. Koren-
berg, and J. A. Fagin, unpublished data). The mapped
BAC resource for chromosome 2 used for the initial
analysis was composed of ∼1 BAC/Mb (245 BACs/285
kb), resulting in the ability to detect ∼70% of duplica-
tions 11 Mb, under the assumption of random distri-
bution. Use of a whole-genome array of BACs at this
density would result in the ability to detect most am-
plification events throughout the genome and to flank
closely most chromosomal rearrangements associated
with tumorigenesis. Such a resource has been generated,
is visible at the Website of the corresponding author of
this article (J.R.K. [Molecular Genetics Labs at CSMC]),
and, in part, has been integrated with the STS and phys-
ical maps of the human genome. This resource will be
of great value for the definition of chromosomal rear-
rangements associated with neoplasia and will be useful
both for gene discovery and, subsequently, to guide di-
agnosis, prognosis, and treatment.
High-Resolution Banding for CGH
This article reports the development and application
of a banding technique employing chromomycin and
distamycin for use with CGH. In contrast to gene map-
ping, in which it is desirable to view the banding pattern
simultaneously with the hybridization probe, the images
generated for CGH, by both the tumor DNA and the
control DNA, must be captured in the absence of light
from any other source but, nonetheless, must be regis-
tered with the banding pattern. Previously, this require-
ment was satisfied by use of three different dyes. For
example, most current techniques rely on DAPI for
banding (Kallioniemi et al. 1994b), which provides a
low-resolution banding pattern. We therefore modified
our higher-resolution, chromomycin A3/distamycin re-
verse-banding technique, so that the banding image was
captured accurately but independent of the hybridization
signals. This technique permits high-resolution assign-
ment of amplified and deleted regions to single human
chromosome bands by CGH alone and provides a means
for defining the more appropriate BACs to be tested for
amplification, as described in the Material and Methods
section.
Amplification and Deletions by CGH
We have reported the analysis of 33 thyroid-tumor
DNAs and two cell-line DNAs and have detected 11
commonly amplified regions plus a single deleted region
that were defined by CGH. It is possible, although it has
not been determined by this study, that each of these
regions contains genes that are amplified in thyroid tu-
mors. These data provide the basis with which to focus
future studies of candidate-gene amplification in thyroid
tumors. Although we have focused on the 2p21 locus,
it is of interest that amplification 2p13-15 has been re-
ported in an extranodal diffuse large-cell lymphoma
(Houldsworth et al. 1996). However, in the present
study, all of the known oncogenes in this region were
excluded on the basis of the lack of both amplification
and overexpression in the WRO cell line, as described
in the Results section.
Previous reports have used CGH to document DNA
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amplifications of similar chromosome bands (e.g., 1p36)
or chromosome arms, including 1q, 2p, 5q, 9q, 14q,
16q, and 19q, from a variety of tumors, including lym-
phomas, colorectal tumors, neuroectodermal tumors, li-
posarcomas, oral squamous-cell carcinoma, and pros-
tate cancers (Matsumura 1995; Bentz et al. 1996;
Bockmuhl et al. 1996; Ried et al. 1996; Schutz et al.
1996; Szymanska et al. 1996). However, these reports
led to the identification of candidate genes that previ-
ously had been known to exist in the region. In contrast,
use of a dense BAC clone array, has, as shown in this
study, provided the critical link to allow the definition
of previously unmapped candidate genes that are to be
identified by a combination of CGH and positional clon-
ing. It may be of interest to determine the relationship
between the 2p21 amplification event involving PKCe,
reported here, and the chromosome 2 inversions asso-
ciated with a previously reported papillary carcinoma
(Lehmann et al. 1997). It will be possible to use the
current approach, employing the BAC resource to define
minimal regions likely to contain oncogenes or tumor-
suppressor genes, for study of the progression of these
tumors. In the tumor collection used in the present study,
more-detailed analysis of aneuploidy was limited by the
lack of tumor materials with which to test candidate
BACs.
Our study may be less quantitative and less sensitive
for analysis of deletion, because the CGH software (On-
cor Imaging) available for this project was not capable
of combining the data across cells. On the other hand,
losses of chromosome 16q also have been seen in high-
grade ovarian tumors (Iwabuchi et al. 1995) and in pros-
tate cancer (Joos et al. 1995; Cher et al. 1996), indicating
the possible presence of tumor suppressors in the region.
Molecular Definition and Size Estimation of the
Amplified Region
Our data revealed that a region on 2p21 was highly
amplified in the WRO cell line with DMs, with a lesser
amplification event on 2p13, providing the opportunity
for a further molecular analysis of these regions. The
present study, therefore, focused on the analysis of these
regions. Furthermore, the DNAs from eight other tumors
also revealed amplification of the same chromosomal
band, 2p21 (table 1), suggesting that this region may
harbor a gene whose overexpression might be involved
in tumor progression. To further analyze the amplifi-
cation event, a 373-member chromosome 2 BAC re-
source was generated, and a subset was used. These
BACs were first mapped to their respective loci on chro-
mosome 2 by multicolor FISH, as illustrated in the re-
ports by Wang et al. (1994) and Chen et al. (1996).
However, only a subset of the BACs mapped to 2p13
and 2p21 were used to investigate amplification in the
WRO cell line. The variability of the signals seen on
different DMs within a single interphase in the WRO
cell population suggests the existence of a minor cell
population with both a higher copy number and a
smaller amplicon size. The results firmly established am-
plification of this region on the DMs. Furthermore, there
was no evidence of the involvement of any other region
of chromosome 2 in the amplification event, in contrast
to the results with chromosome 20 that are seen in the
study of breast cancer (Kallioniemi et al. 1994a).
Both of the map-based distance estimations (i.e., RH
and genetic-marker map) represented averages for the
entire human genome and were associated with signif-
icant variation for a given region. It is of interest that
the estimate derived from the molecular cytogenetic data
fell between these two and, given the lesser variation in
chromosome condensation, likely represented a reason-
able measure. However, it is important to note that all
estimates may be gross overestimates of the true size of
the amplified region in the DMs seen in WRO, because,
in each case, the flanking BACs or markers were located
at an unspecified distance from the amplified region. It
is of note that these estimations of maximal size of the
amplified region are small when compared with those
determined by most previous CGH analyses, which in-
cluded a number of bands or an entire chromosome arm.
It is important to note that the resolution obtained in
this study is possible for the entire genome using the
currently available resource. Given the density of this
resource, it represents an alternative to chromosomemi-
crodissection, for definition of the regions amplified in
DMs (Guan et al. 1994).
BAC Characterization and Gene Identification
The amplified contig defined in this study may contain
the ends of the amplicon and, therefore, could provide
the tools with which to isolate further candidate genes.
This could be established by extension of the contig and
evaluation of cytological preparations that may be more
sensitive for detection of low-frequency amplification.
Further evaluation of the structure and expression of
the PKCe region in WRO revealed a structural rear-
rangement involving the gene (fig. 6), which resulted in
the overexpression of a hybrid molecule, as seen on
northern analyses (data not shown; J. A. Knauf, R. Elisei,
D. Mochly-Rosen, T. Liron, X.-N. Chen, J. R. Koren-
berg, and J. A. Fagin, unpublished data). The altered
function of this molecule in the signal-transduction cas-
cade may have been a significant event in the transfor-
mation of this tumor clone (J. A. Knauf, R. Elisei, D.
Mochly-Rosen, T. Liron, X.-N. Chen, J. R. Korenberg,
and J. A. Fagin, unpublished data). This possible role
for PKCe in thyroid tumorigenesis is supported by pre-
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vious reports, which implicated abnormal PKCe expres-
sion in endocrine tumors (Kuranami et al. 1995).
It is of interest that significant amplification of 2p21
was clearly observed by CGH only in the cell line car-
rying DMs. Taken together with the observation of a
genomic rearrangement and expression of a truncated
gene product, this may indicate that mutation or rear-
rangement—rather than overexpression—of PKCe may
be responsible for its role in thyroid tumorigenesis. This
finding indicates that identification of uncommon events
such as amplification may point to genes whose role in
tumorigenesis may involve more-complex mechanisms.
In summary, CGH has been successful in identification
of candidate genes likely to be involved in tumorigenesis.
At present, only a few human chromosomes (2, 6p, 11p,
16, 19, 21, X, and Y) are relatively well covered with
large-fragment vector arrays—such as cosmids, BACs,
or PACs—that are suitable either for use in definition of
amplified regions or to be fixed, as CGH targets, as
arrays on glass chips. Our current chromosome 2 re-
source (Wang et al. 1994), as well as our integrated
genomewide BAC and PAC resource (Chen et al. 1996),
represents a very powerful tool for this purpose. Four
aspects of the current approach are of importance. First,
the higher-resolution R-banding method facilitates the
assignment of the amplified region to a chromosome
band and links the amplified region with the phys-
ical map. Second, the availability of chromosome-
band–specific BACs and PACs that represent 125% of
the genome greatly facilitates the speed with which a
subset of BACs mapping in an amplified region can be
determined. Third, the existence of the integrated BAC
and PAC resource linked to STS information establishes
the link to both the physical and genetic maps, which,
in turn, provides markers for rapid completion of a BAC
and PAC array and for establishment of the gene/EST
candidates for roles in tumorigenesis. Fourth, the current
large-scale sequencing used in combination with this ap-
proach provides the ability to rapidly identify candidate
genes involved in tumor progression.
It is of importance to note that these technical ad-
vances are equally powerful in translating the rapidly
developing application of CGH to genomic DNAs im-
mobilized either on glass slides or, ultimately, on com-
puter chips (Cheung and Nelson 1996). The establish-
ment of mapped, integrated, and partially ordered
large-fragment (BAC or PAC) clone arrays that represent
a large proportion of the human genome becomes es-
sential both for maximization of the probability of find-
ing amplification events and for rapid translation of
these into a series of candidate genes. In the present
study, the next steps have been taken and the entire
approach has been illustrated: the sequencing of an en-
tire BAC located in the amplified region has revealed the
gene encoding PKCe, which has led to the demonstration
of both a genomic rearrangement and overexpression of
the chimeric gene product. As described elsewhere (J. A.
Knauf, R. Elisei, D. Mochly-Rosen, T. Liron, X.-N.
Chen, J. R. Korenberg, J. A. Fagin, unpublished data),
the product may selectively impair programmed cell
death in thyroid cells, thus demonstrating that the ge-
netic-amplification event detected by CGH coupled with
the mapped BAC resource has identified a legitimate
candidate tumor-promoting gene that likely plays a role
in oncogenesis.
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Appendix
List of Thyroid Tumors Tested
Follicular
Adenoma
( )n  10
Follicular
Carcinoma
( )n  5
Papillary
Carcinoma ( )n  18
Anaplastic
Carcinoma
( )n  2
60 R15 WRO 146 R2 R7 R12 ARO
A9 R16 FRO 162 R3 R8 A4 82I
A19 R17 J3 163 R4 R9 NPA
R13 R18 J4 165 R5 R10
R14 115 R19 R1 R6 R11
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